Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    " April 22, 2009":" May 22, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" April 22, 2009":" May 22, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (33 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: ADVAX;   Biological: TBC-M4;   Other: Placebo
2 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
3 Completed HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan Armenia
Conditions: HIV Prevention;   HIV Infections
Intervention: Behavioral: HIV risk reduction intervention
4 Active, not recruiting Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients
Conditions: HIV Infections;   Memory
Intervention:
5 Completed Linkage to Care - Part II
Conditions: HIV;   Care-seeking;   HIV Infections
Interventions: Other: Case Management;   Other: Snowball sampling;   Other: Referral Lists
6 Unknown  Raltegravir in the Swiss HIV Cohort Study
Condition: HIV Infection
Intervention: Drug: Raltegravir
7 Completed Empowerment Intervention for Young Women - Phase I
Conditions: HIV;   Empowerment;   HIV Infections
Intervention: Behavioral: Prevention Empowerment Intervention for Young Women
8 Completed TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
Condition: HIV Infections
Intervention: Drug: TMC207; nevirapine
9 Unknown  Cognitive and Psychosocial Benefits of MISC Training for Ugandan Children
Conditions: HIV;   HIV Infections
Intervention: Behavioral: MISC training for primary caregivers
10 Withdrawn PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
Condition: HIV Infections
Interventions: Drug: TMC589337 40 mg;   Drug: TMC589337 100 mg;   Drug: TMC589337 200 mg;   Drug: TMC589337 400 mg;   Drug: TMC589354 40 mg;   Drug: TMC589354 100 mg;   Drug: TMC589354 200 mg;   Drug: TMC589354 400 mg;   Drug: TMC589337 AA mg;   Drug: TMC589354 BB mg;   Drug: TMC589337 CC mg;   Drug: TMC589354 DD mg;   Drug: TMC589337 EE mg;   Drug: TMC589354 YY mg;   Drug: TMC310911 300 mg;   Drug: TMC310911 600 mg;   Drug: Placebo
11 Completed
Has Results
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
Condition: HIV Infections
Interventions: Drug: Nevirapine Immediate Release (IR);   Drug: Nevirapine Extended Release (XR)
12 Unknown  HIV and Kidney Function Study
Conditions: HIV Infections;   AIDS
Intervention:
13 Completed Hepatitis B Vaccination (HBV) in HIV Infected Children
Condition: HIV Infections
Interventions: Biological: Intradermal HBV 1 course;   Biological: Intramuscular HBV I course
14 Completed Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ Patients
Conditions: HIV Infections;   COPD
Intervention:
15 Completed
Has Results
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Atazanavir (ATV) 300 mg;   Drug: Atazanavir (ATV) 400 mg;   Drug: Ritonavir (rtv) 100 mg;   Drug: Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs);   Drug: Etravirine (ETR) 200 mg;   Drug: Tenofovir disoproxil fumarate (TDF) 300 mg
16 Completed
Has Results
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
Conditions: Hypercholesterolemia;   HIV Infections
Interventions: Drug: Ezetimibe;   Drug: Rosuvastatin (standard care)
17 Completed Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid
Conditions: Human Immunodeficiency Virus Infections;   HIV Infections
Interventions: Biological: tgAAC09;   Other: Formulation buffer
18 Completed Efficacy and Safety of Single Versus Double Ritonavir-Boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: ritonavir-boosted PI-based second line treatments;   Drug: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
19 Completed
Has Results
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
Conditions: Anxiety Disorders;   HIV Infections
Intervention: Drug: Escitalopram
20 Completed
Has Results
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients
Conditions: HIV Infection;   HIV;   Acquired Immunodeficiency Syndrome
Interventions: Drug: etravirine (ETR, TMC125);   Drug: efavirenz (EFV)

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.